| 1 | Zhang, Ge, Yu, Yuanyuan, Ni, Shuaijian, He, Yixin, "An aptamer for sclerostin and a use thereof, specifically a use in the treatment of sclerostin-associated diseases such as osteoporosis". 15/09/2029, International patent, WO/2019/154410 |
| 2 | 张戈;于媛媛;倪帅健;何伊欣. “针对骨硬化蛋白的适体及其用途” CN 111712573 B，发明专利，中华人民共和国 |
| 3 | 张戈;于媛媛;倪帅健. “针对骨硬化蛋白的适体及其用途” 7120531，发明专利，日本 |
| 4 | Ge Zhang. APTAMER FOR SCLEROSTIN AND USE THEREOF, PCT/CN2019/074764, USA |
| 5 | APTACURE THERAPEUTICS LIMITED, et al. APTAMER FOR SCLEROSTIN AND USE THEREOF, PCT/CN2019074764, Europe |
| 6 | Yu Y, Chu HY, He Y, Zhang G. (2022) Aptamers against DKK1 and their applications (202280043227.7) |
| 7 | Zhang, Ge, Wang, Luyao, et al., "Molecular Mechanisms and Clinical Precision Diagnosis and Treatment of Hereditary Bone Diseases", First Prize of the 2023 Shanghai Medical Science and Technology Award |
| 8 | Zhang Ge, et al. The Representative Achievement In Medical and Health Sciences in The 25th Anniversary of The Reunification of HK SAR |
| 9 | Ma Y, et al. "Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential." Young Scientist Award of 2024 - 10th Edition of International Research Awards on Genetics and Genomics of Diseases. Paris, France |
| 10 | A new nucleic acid aptamer drug for the treatment of Osteogenesis Imperfecta, US FDA, (DRU-2019-6966) |
| 11 | The long-acting sclerostin-loop3 nucleic acid aptamer Apc001OA for the treatment of Osteogenesis Imperfecta was granted Orphan Drug Designation (DRU-2022-9087) by the U.S. FDA on 14/08/2022. |
| 12 | The long-acting sclerostin-loop3 nucleic acid aptamer Apc001OA for the treatment of Osteogenesis Imperfecta was granted Pediatric Rare Disease Designation (RPD-2022-667) by the U.S. FDA on 21/08/2022. |
| 13 | The long-acting sclerostin-loop3 nucleic acid aptamer Apc001OA for the treatment of X-linked hypophosphatemia was granted Orphan Drug Designation (DRU-2023-9894) by the U.S. FDA on 22/02/2024. |
| 14 | The long-acting sclerostin-loop3 nucleic acid aptamer Apc001OA for the treatment of X-linked hypophosphatemia was granted Pediatric Rare Disease Designation (RPD-2023-780) by the U.S. FDA on 22/02/2024. |
| 15 | The long-acting CTGF CT-domain nucleic acid aptamer Apc003OA for the treatment of Duchenne Muscular Dystrophy was granted Orphan Drug Designation (DRU-2024-10138) by the U.S. FDA on 29/04/2024. |
| 16 | The long-acting CTGF CT-domain nucleic acid aptamer Apc003OA for the treatment of Duchenne Muscular Dystrophy was granted Pediatric Rare Disease Designation (RPD-2024-838) by the U.S. FDA on 01/05/2024. |
| 17 | The long-acting DKK1 nucleic acid aptamer-based PROTAC Apc102 for the treatment of Gastric cancer was granted Orphan Drug Designation (DRU-2024-10338) by the U.S. FDA on 17/07/2024. |
| 18 | Yu, S., Li, D., Zhang, N., Ni, S., Sun, M., Wang, L., Xiao, H., Liu, D., Liu, J., Yu, Y., Zhang, Z., Yeung, S. T. Y., Zhang, S., Lu, A., Zhang, Z., Zhang, B., & Zhang, G. (2022). Drug discovery of sclerostin inhibitors. Acta pharmaceutica Sinica. B, 12(5), 2150–2170. https://doi.org/10.1016/j.apsb.2022.01.012 |
| 19 | Zhang, H., Yu, S., Ni, S., Gubu, A., Ma, Y., Zhang, Y., Li, H., Wang, Y., Wang, L., Zhang, Z., Yu, Y., Lyu, A., Zhang, B., & Zhang, G. (2023). A bimolecular modification strategy for developing long-lasting bone anabolic aptamer. Molecular therapy. Nucleic acids, 34, 102073. https://doi.org/10.1016/j.omtn.2023.102073 |
| 20 | Yu, S., Huang, W., Zhang, H., Guo, Y., Zhang, B., Zhang, G., & Lei, J. (2024). Discovery of the small molecular inhibitors against sclerostin loop3 as potential anti-osteoporosis agents by structural based virtual screening and molecular design. European journal of medicinal chemistry, 271, 116414. https://doi.org/10.1016/j.ejmech.2024.116414 |
| 21 | Zhang, Y., Zhang, H., Chan, D. W. H., Ma, Y., Lu, A., Yu, S., Zhang, B., & Zhang, G. (2022). Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future. Frontiers in cell and developmental biology, 10, 1048148. https://doi.org/10.3389/fcell.2022.1048148 |
| 22 | Amu, G., Yang, X., Luo, H., Yu, S., Zhang, H., Tian, Y., ... & Zhang, G. (2025). Machine learning-powered, high-affinity modification strategies for aptamers. Acta Materia Medica, 4(1), 122-136. |
| 23 | Ma, Y., Zhang, H., Shen, X., Yang, X., Deng, Y., Tian, Y., Chen, Z., Pan, Y., Luo, H., Zhong, C., Yu, S., Lu, A., Zhang, B., Tang, T., & Zhang, G. (2024). Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy. Cancer letters, 598, 217102. https://doi.org/10.1016/j.canlet.2024.217102 |
| 24 | Ma, Y., Xie, D., Chen, Z., Shen, X., Wu, X., Ding, F., Ding, S., Pan, Y., Li, F., Lu, A., & Zhang, G. (2024). Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release. Journal of translational medicine, 22(1), 604. https://doi.org/10.1186/s12967-024-05429-8 |
| 25 | Gubu, A., Ma, Y., Yu, S., Zhang, H., Chen, Z., Ni, S., Abdullah, R., Xiao, H., Zhang, Y., Dai, H., Luo, H., Yu, Y., Wang, L., Jiang, H., Zhang, N., Tian, Y., Li, H., Lu, A., Zhang, B., & Zhang, G. (2024). Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential. Molecular therapy. Nucleic acids, 35(1), 102146. https://doi.org/10.1016/j.omtn.2024.102146 |
| 26 | Ma, Y., Zhang, Y., Chen, Z., Tian, Y., & Zhang, G. (2023). The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates. In R. Mithun (Ed.), Drug Metabolism and Pharmacokinetics (pp. Ch. 6). IntechOpen. https://doi.org/10.5772/intechopen.112756 |
| 27 | Chen, Z., Luo, H., Gubu, A., Yu, S., Zhang, H, Dai, H., Zhang, Y., Zhang, B., Ma, Y., Lu, A., & Zhang, G. (2023). Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding. Frontiers in cell and developmental biology, 11, 1091809. https://doi.org/10.3389/fcell.2023.1091809 |
| 28 | Gubu, A., Zhang, X., Lu, A., Zhang, B., Ma, Y., & Zhang, G. (2023). Nucleic acid amphiphiles: Synthesis, properties, and applications. Molecular therapy. Nucleic acids, 33, 144–163. https://doi.org/10.1016/j.omtn.2023.05.022 |
| 29 | Dai, H., Abdullah, R., Wu, X., Li, F., Ma, Y., Lu, A., & Zhang, G. (2022). Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy. Frontiers in cell and developmental biology, 10, 855474. https://doi.org/10.3389/fcell.2022.855474 |
| 30 | Ma, Y., Yu, S., Ni, S., Zhang, B., Kung, A. C. F., Gao, J., Lu, A., & Zhang, G. (2021). Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy. Frontiers in cell and developmental biology, 9, 626910. https://doi.org/10.3389/fcell.2021.626910 |
| 31 | Wang, L., Yu, Y., Ni, S., Li, D., Liu, J., Xie, D., Chu, H. Y., Ren, Q., Zhong, C., Zhang, N., Li, N., Sun, M., Zhang, Z. K., Zhuo, Z., Zhang, H., Zhang, S., Li, M., Xia, W., Zhang, Z., Chen, L., … Zhang, G. (2022). Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice. Theranostics, 12(13), 5645–5674. https://doi.org/10.7150/thno.63177 |
| 32 | Yu, Y., Liu, M., Choi, V. N. T., Cheung, Y. W., & Tanner, J. A. (2022). Selection and characterization of DNA aptamers inhibiting a druggable target of osteoarthritis, ADAMTS-5. Biochimie, 201, 168–176. https://doi.org/10.1016/j.biochi.2022.06.001 |
| 33 | Yu, Y., Wang, L., Ni, S., Li, D., Liu, J., Chu, H. Y., Zhang, N., Sun, M., Li, N., Ren, Q., Zhuo, Z., Zhong, C., Xie, D., Li, Y., Zhang, Z. K., Zhang, H., Li, M., Zhang, Z., Chen, L., Pan, X., … Zhang, G. (2022). Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nature communications, 13(1), 4241. https://doi.org/10.1038/s41467-022-31997-8 |
| 34 | Yang, X., Chan, C. H., Yao, S., Chu, H. Y., Lyu, M., Chen, Z., Xiao, H., Ma, Y., Yu, S., Li, F., Liu, J., Wang, L., Zhang, Z., Zhang, B. T., Zhang, L., Lu, A., Wang, Y., Zhang, G., & Yu, Y. (2024). DeepAptamer: Advancing high-affinity aptamer discovery with a hybrid deep learning model. Molecular therapy. Nucleic acids, 36(1), 102436. https://doi.org/10.1016/j.omtn.2024.102436 |
| 35 | Chen, Z., Hu, L., Zhang, B. T., Lu, A., Wang, Y., Yu, Y., & Zhang, G. (2021). Artificial Intelligence in Aptamer-Target Binding Prediction. International journal of molecular sciences, 22(7), 3605. https://doi.org/10.3390/ijms22073605 |
| 36 | Liu, J., Wu, X., Lu, J., Huang, G., Dang, L., Zhang, H., Zhong, C., Zhang, Z., Li, D., Li, F., Liang, C., Yu, Y., Zhang, B. T., Chen, L., Lu, A., & Zhang, G. (2021). Exosomal transfer of osteoclast-derived miRNAs to chondrocytes contributes to osteoarthritis progression. Nature aging, 1(4), 368–384. https://doi.org/10.1038/s43587-021-00050-6 |
| 37 | Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y, Wang, S., Zhong, C., Yu, S., Ren, M., Sun, M., Li, N., Chen, T., Ma, Y., Li, F., Liu, J., Yu, Y,… Zhang, G. (2024). Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives. Journal of orthopaedic translation, 47, 39–49. https://doi.org/10.1016/j.jot.2024.05.004 |
| 38 | Zhong, C., Li, N., Wang, S., Li, D., Yang, Z., Du, L., Huang, G., Li, H., Yeung, W. S., He, S., Ma, S., Wang, Z., Jiang, H., Zhang, H., Li, Z., Wen, X., Xue, S., Tao, X., Li, H., Xie, D,… Zhang, G. (2024). Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity. Nature communications, 15(1), 8588. https://doi.org/10.1038/s41467-024-52965-4 |
| 39 | Zhang, N., Chen, Z., Liu, D., Jiang, H., Zhang, Z. K., Lu, A., Zhang, B. T., Yu, Y., & Zhang, G. (2021). Structural Biology for the Molecular Insight between Aptamers and Target Proteins. International journal of molecular sciences, 22(8), 4093. https://doi.org/10.3390/ijms22084093 |
| 40 | Zhang, N., Zhang, Z. K., Yu, Y., Zhuo, Z., Zhang, G., & Zhang, B. T. (2020). Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. Frontiers in cell and developmental biology, 8, 325. https://doi.org/10.3389/fcell.2020.00325 |
| 41 | Wang, L., Zhang, N., Liu, J., Yang, X., Yu, Y., Li, D., ... & Zhang, G. (2023). Macrophagic sclerostin loop2-ApoER2 interaction required by sclerostin for suppressing inflammatory responses. Metabolism-Clinical and Experimental, 142. |
| 42 | Jiang, H., Li, D., Han, Y., Li, N., Tao, X., Liu, J., Zhang, Z., Yu, Y., Wang, L., Yu, S., Zhang, N., Xiao, H., Yang, X., Zhang, Y., Zhang, G., & Zhang, B. T. (2023). The role of sclerostin in lipid and glucose metabolism disorders. Biochemical pharmacology, 215, 115694. https://doi.org/10.1016/j.bcp.2023.115694 |
| 43 | Jiang, H., Li, D., Wang, L., Zhang, N., Yu, S., Zhang, H., ... & Zhang, G. (2023). Sclerostin loop3-LRP4 Interaction Required by Sclerostin for Lipid and Glucose Metabolism Impairment in Adipocyte. Metabolism-Clinical and Experimental, 142. |